AP
APLM.US Apollomics Inc. Class A Ordinary Shares
- Market cap
- USD 51.5M
- P/E
- -
- P/B
- 8.12x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is APLM.US undervalued?
Graham numberThe Graham number of Apollomics Inc. Class A Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Apollomics Inc. Class A Ordinary Shares fundamental analysis
No fundamental analysis for Apollomics Inc. Class A Ordinary Shares yet.
Apollomics Inc. Class A Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral acti…
Full company profileApollomics Inc. Class A Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Apollomics Inc. Class A Ordinary Shares annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 1.84M | 2.00K | 323K | 821K | 198K | 8.50M | - |
| Gross Profit | -369K | 1.84M | 2.00K | 323K | 821K | 198K | 8.25M | - |
| Operating Income | -24.7M | -40.6M | -50.9M | -45.1M | -54.0M | -42.1M | -9.47M | -15.2M |
| EBITDA | -45.3M | -40.0M | -49.6M | -43.3M | -52.9M | -40.8M | -9.22M | -11.2M |
| Net Income | -45.9M | -74.8M | -94.8M | -241M | -173M | -53.9M | -10.9M | -14.4M |
| EPS | -53 | -86 | -109 | -277 | -232 | -58 | -7.57 | -6.64 |
| Balance Sheet | ||||||||
| Total Assets | 79.1M | 170M | 123M | 76.5M | 55.4M | 13.1M | 6.71M | 2.21M |
| Total Liabilities | 140M | 298M | 336M | 525M | 14.2M | 8.23M | 9.90M | 13.0M |
| Shareholders' Equity | -60.7M | -128M | -213M | -448M | 41.2M | 4.86M | -3.19M | -10.8M |
| Cash & Short-term Investments | 74.1M | 154M | 94.5M | 54.6M | 37.8M | 9.77M | 3.28M | 1.01M |
| Total Debt | 136M | 290M | 325M | 991K | 4.66M | 966K | 643K | 1.87M |
| Cash Flow | ||||||||
| Operating Cash Flow | -21.9M | -35.7M | -43.3M | -42.8M | -43.2M | -28.7M | -10.4M | -41.5M |
| Capital Expenditure | 857K | 144K | 7.55M | 367K | 6.00K | 24.0K | 0.00 | 0.00 |
| Free Cash Flow | -22.8M | -35.8M | -50.9M | -43.2M | -43.2M | -28.8M | -10.4M | -41.5M |
| Ratios | ||||||||
| ROE | - | - | - | - | -418.6% | -1,107.3% | - | - |
| ROA | -58.1% | -44.0% | -76.8% | -314.9% | -311.6% | -411.2% | -162.9% | -652.3% |
| Net Profit Margin | - | -4,070.7% | -4,739,850.0% | -74,554.5% | -21,023.3% | -27,201.0% | -128.7% | - |
| Debt to Equity | - | - | - | - | 0.11x | 0.20x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Apollomics Inc. Class A Ordinary Shares dividends
Apollomics Inc. Class A Ordinary Shares has not paid dividends in the last 7 fiscal years.
Last stock split: 1:100 on Nov 25, 2024.
Who owns Apollomics Inc. Class A Ordinary Shares
- Insiders 56.46%
- Institutions 0.42%
- Public & others 43.12%
- Shares outstanding 2.91M
- Free float 535K
Top funds holding APLM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 1.65K | 0.06% | 0.00% | Aug 2026 |
Top institutions holding APLM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 10.7K | 0.37% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 9.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 2.00 | 0.00% | -98.59% | Jun 2026 |
| BlackRock Inc | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Apollomics Inc. Class A Ordinary Shares company profile
- Company name
- Apollomics Inc. Class A Ordinary Shares
- Ticker
- APLM.US
- ISIN
- KYG0411D1236
- Exchange
- USA Stocks
- Listed since
- Nov 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 989 East Hillsdale Blvd., Foster City, CA, United States, 94404
- Phone
- 650 209 4055
- Website
- apollomicsinc.com
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Apollomics Inc. Class A Ordinary Shares management
3- Mr. Hung-Wen ChenCEO & Chairman of the Board · born 1961
- Mr. K. H. Lin C.A.I.A., M.B.A.Chief Financial Officer · born 1970
- Mr. Yi-Kuei ChenDirector & COO · born 1970